Close

Arbutus Biopharma (ABUS) Announces Results from Phase II Trial of ARB-1467 for Chronic HBV Infection

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. TSLA
2. META
3. ENPH
4. TXN
5. BA
6. SPOT
7. IBM
8. V
9. HCP
10. KMB


Go back to Arbutus Biopharma (ABUS) Announces Results from Phase II Trial of ARB-1467 for Chronic HBV Infection
(NASDAQ: ABUS) Delayed: 2.75 --0 (-0%)
Previous Close $2.75    52 Week High $5.88 
Open $2.75    52 Week Low $2.65 
Day High $2.78    P/E N/A 
Day Low $2.74    EPS $0.00 
Volume 345,057